It is well known that sleep disorders are harmful to people's health and performance, and growing evidence suggests that sleep deprivation (SD) can trigger neuroinflammation in the brain. The nucleotide-binding domain and leucine-rich repeat protein-3 (NLRP3) inflammasome is reported to be relevant to the neuroinflammation induced by SD, but the regulatory signaling that governs the NLRP3 inflammasome in SD is still unknown. Meanwhile, whether the regulatory action of antidepressants in astrocytes could affect the neuroinflammation induced by SD also remains obscure. In this study, we were the first to discover that the antidepressant fluoxetine, a type of specific serotonin reuptake inhibitor widely used in clinical practice, could suppress the neuroinflammation and neuronal apoptosis induced by SD. The main findings from this study are as follows: (i) SD stimulated the expression of activated NLRP3 inflammasomes and the maturation of IL-1b/18 via suppressing the phosphorylation of STAT3 in astrocytes; (ii) SD decreased the activation of AKT and stimulated the phosphorylation of GSK-3b, which inhibited the phosphorylation of STAT3; (iii) the NLRP3 inflammasome expression stimulated by SD was partly mediated by the P2X7 receptor; (iv) an agonist of STAT3 could significantly abolish the expression of NLRP3 inflammasomes induced by an agonist of the P2X7 receptor in primary cultured astrocytes; (v) the administration of fluoxetine could reverse the stimulation of NLRP3 inflammasome expression and function by SD through elevating the activation of STAT3. In conclusion, our present research suggests the promising possibility that fluoxetine could ameliorate the neuronal impairment induced by SD. Keywords: astrocytes, fluoxetine, NLRP3 inflammasomes, sleep deprivation, STAT3. Abbreviations used: ASC, apoptosis-associated speck-like protein containing a CARD; CUMS, chronic unpredictable mild stress; DAPI, 4 0 ,6-diamidine-2-phenylindole; dBcAMP, dibutyryl cyclic AMP; DMEM, Dulbecco's modified Eagle's medium; EGFR, epidermal growth factor receptor; GFP, green fluorescent protein; GSK-3b, glycogen synthase kinase-3b; MDD, major depressive disorder; NLR, nucleotide-binding oligomerization domain-like receptor; NLRP3, nucleotide-binding domain and leucine-rich repeat protein-3; P2X 7 R-KO, P2X7 receptor knockout; PI3K, phosphatidylinositol-3-kinase; RTK, receptor tyrosine kinase; SD, sleep deprivation; SSRIs, specific serotonin reuptake inhibitors; STAT3, signal transducer and activator of transcription 3.
suppressing the phosphorylation of STAT3 in astrocytes; (ii) SD decreased the activation of AKT and stimulated the phosphorylation of GSK-3b, which inhibited the phosphorylation of STAT3; (iii) the NLRP3 inflammasome expression stimulated by SD was partly mediated by the P2X7 receptor; (iv) an agonist of STAT3 could significantly abolish the expression of NLRP3 inflammasomes induced by an agonist of the P2X7 receptor in primary cultured astrocytes; (v) the administration of fluoxetine could reverse the stimulation of NLRP3 inflammasome expression and function by SD through elevating the activation of STAT3. In conclusion, our present research suggests the promising possibility that fluoxetine could ameliorate the neuronal impairment induced by SD. Keywords: astrocytes, fluoxetine, NLRP3 inflammasomes, sleep deprivation, STAT3. J. Neurochem. (2018) 146, 63--75. Sleep is indispensable for human life, and reduced or disrupted sleep is harmful to cognition, emotional wellbeing, and overall health. Sleep deprivation (SD) impairs several physiological processes, including immunity and cognition (Irwin et al. 2008 ; Van-Cauter et al. 2008) . Recently, growing evidence has suggested that SD can trigger neuroinflammation (Zielinski et al. 2017) . The nucleotide-binding domain and leucine-rich repeat protein-3 (NLRP3) inflammasome contributes to neuronal damage in several pathological states, particularly, in mood disorders and cognitive diseases as well as in SD, although peculiarities of the regulation of the NLRP3 inflammasome in the latter pathology remain unclear (Sahin et al. 2016; VanItallie 2017; Zielinski et al. 2017) . Treatment with fluoxetine (a widely used antidepressant) inhibits activation of NLRP3 inflammasome in major depressive disorder (Alcocer-G omez et al. 2017) . Based on this evidence, we addressed the question of whether the activation of NLRP3 inflammasome induced by SD could be reversed by fluoxetine.
Astroglia, the homeostatic cells of the brain (Verkhratsky and Nedergaard 2016) , contribute to the majority of neurological disorders (Pekny et al. 2016) . In particular, astrocytes play a primary role in various neuropsychiatric diseases; in major depressive disorders, astrocytes undergo atrophy and pathological remodeling (Verkhratsky et al. 2014; Wang et al. 2017) . Our previous studies demonstrated that antidepressant fluoxetine, a type of specific serotonin reuptake inhibitor, exerts therapeutic action by directly stimulating astroglial 5-HT 2B receptors (Peng et al. 2014; Hertz et al. 2015) . Antidepressants have been also considered clinically effective for treating the SD (Giedke et al. 1990 ). The rapid eye movement latency has been suggested an indicator of depression (Kupfer and Foster 1972) , and long-term sleep disturbance causes health damage; for example, it elevates the risk of metabolic and mental disorders (Dworak et al. 2011; Armitage, 2007) . Moreover, in a long-term SD model, the underlying regulatory effects of fluoxetine on astrocytes remain poorly understood.
The NLR protein family includes the NLRP1-14 and ICEprotease-activating factor subfamilies, which form inflammasome complexes in response to various forms of physiological or pathological stimulation (Jian et al. 2016; Wong et al. 2016) . In the NLRP3 inflammasome, the NLRP3 scaffold interacts directly with the adaptor molecule apoptosis-associated speck-like protein containing a CARD (ASC), which promotes the activation of cysteine protease caspase 1 from the inactive precursor pro-caspase 1. Activated caspase 1, in turn, triggers the maturation of pro-IL-1b to IL-1b or of pro-IL-18 to IL-18 and the secretion of the product (Zielinski et al. 2017) . Extracellular ATP, acting through the ionotropic P2X 7 receptor (P2X 7 R), leads to K + efflux, which is required for NLRP3 inflammasome activation (Pelegrin and Surprenant 2007; Karmakar et al. 2016) . Activation of the P2X 7 receptor with subsequent stimulation of the NLRP3 inflammasome in the mouse hippocampus induced depression-like behaviors (Yue et al. 2017) . The level of ATP in the cortex increases during sleep deprivation (Dworak et al. 2010) . However, whether P2X 7 R is involved in the activation of the NLRP3 inflammasome in SD remains unknown. In addition, chronic unpredictable mild stress increases the activation of glycogen synthase kinase-3b (GSK-3b), and the latter inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and up-regulates the expression of NLRP3 (Liu et al. 2015) . Moreover, fluoxetine can activate the signaling pathways of phosphatidylinositol-3-kinase (PI3K)/AKT and MAPK/ ERK 1/2 by transactivating the epidermal growth factor receptor (EGFR) in astrocytes (Li et al. 2008; Ren et al. 2015) . In astrocytic or C2C12 cells, there is crosstalk between PI3K/AKT and MAPK/ERK 1/2 (Pijet et al. 2013; Ren et al. 2015) , and these two signaling pathways both regulate the activation of STAT3 (Pijet et al. 2013; Liu et al. 2015) . However, the exact regulatory effect of fluoxetine on the phosphorylation of STAT3 is still unknown in astrocytes, particularly under the pathological condition of sleep deprivation.
In this study, we found that SD induced P2X7R-mediated formation of NLRP3 inflammasomes in astrocytes, which promoted atsroglial release of IL-1b and IL-18 that exerted neurotoxicity. The antidepressant fluoxetine increased the activation of STAT3 and suppressed formation of the NLRP3 inflammasome, thus preventing SD-induced neuronal impairment.
Experimental procedures
Animals As in our previous research (Xia et al. 2017 ), C57BL/6 (B6; #000664, RRID:IMSR_JAX:000664), FVB/N-Tg(GFAPGFP) 14Mes/J (GFAP-GFP; #003257, RRID:IMSR_JAX:003257), and B6.129P2-P2rx7 tm1Gab /J (P2X7R-KO; #005576, RRID: IMSR_JAX:005576) mice (all purchased from the Jackson Laboratory, Bar Harbor, ME, USA) were used. Newborn B6 mice were bred in the experimental animal center of China Medical University. Experiments were performed on 3-month-old male mice (~25 g), which were kept in standard housing conditions (22 AE 1°C; light/ dark cycle of 12/12 h) with food and water available ad libitum. All B6, GFAP-green fluorescent protein (GFP) and P2X7R-KO mice were randomly assigned to different experimental groups with a random number table. All operations were carried out in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 8023) and its 1978 revision. All experimental protocols were checked and approved by the Institutional Animal Care and Use Committee of China Medical University. The study was not pre-registered. To minimize the numbers of animals used, we improved the experimental design and statistical analysis used in this study. The number of animals used in every experimental group was six, it is the lowest number for the experimental design in vivo, considering the effective statistical analysis. The built model of sleep deprivation in this study was a non-invasive method which could not trigger the pain sense of animals. Unless the anesthesia was operated, the mice were intraperitoneally injected with ketamine (80 mg/kg) and xylazine (10 mg/kg). Sleep deprivation and drug treatment Sleep deprivation (SD) was induced by 'gentle handling' according to standard protocols (Franken et al. 1991) , including the introduction of new objects into the cage or gentle touching with a brush to keep the mice awake. SD was induced for 6 h, which began at 7 am and ended at 1 pm. During SD, the mice continually had access to food and water. Animals in the sham group were kept undisturbed in a separate room with the same light/dark cycle as the SD group. The treatment with SD was continued for 1-5 weeks. This study adopted the commonly used time point of 3 weeks; the experimental timeline is shown in Figure S1 . The mice were treated with sham or SD stimulation for 3 weeks. During the third week, U0126 (10 lmol in 2 lL for intracerebroventricular infusion), LY294002 (10 lmol in 2 lL for intracerebroventricular infusion), or vehicle (artificial cerebrospinal fluid) was injected each day; 30 min later, fluoxetine (10 mg/kg) or normal saline was injected intraperitoneally.
Materials
Primary culture of astrocytes Astrocytes were cultured as described previously (Li et al. 2008 (Li et al. , 2011 ; in brief, primary cultures of mouse astrocytes were prepared from the cerebral hemispheres of newborn C57BL/6 mice. Cells were grown in Dulbecco's modified Eagle's medium with 7.5 mM glucose. For the entire third week, 0.25 mM dibutyryl cyclic AMP was included in the medium. All dishes of primary cultured astrocytes were labeled with numbers and randomly separated into different experimental groups with a random number table.
Immunohistochemistry The brain tissue was fixed by immersion in 4% paraformaldehyde and cut into 100 lm slices. Immunohistochemistry was performed as previously described (Xia et al. 2017) . The following primary antibodies were used: mouse anti-phosphorylated STAT3 (1 : 200), rabbit anti-NeuN (1 : 250) (MABN140; RRID:AB_2571567), chicken anti-GFAP (1 : 200) (MAB3402C3; RRID: AB_10916759). The slices were incubated with Alexa Fluorconjugated secondary antibodies for 2 h at 20°C (1 : 450). DAPI (1 : 2000) was used to identify cell nuclei. Immunofluorescence was imaged using a confocal scanning microscope (IX81; Olympus, Tokyo, Japan). To evaluate the level of phosphorylated STAT3 (p-STAT3), we measured the mean intensity of p-STAT3 immunofluorescence within cortical regions. The background intensity of each image was measured in cell-free parenchyma in the same field of view and subtracted from the total immunofluorescence intensity. The intensity of p-STAT3 immunofluorescence from each group was normalized to the intensity of the control group.
TUNEL staining and analysis
To evaluate neuronal apoptosis in the frontal cortex, we performed TdT-mediated dUTP-biotin nick end labeling (TUNEL) in conjunction with immunofluorescent staining for NeuN as described by Chen et al. (2017) . Briefly, the formalin-fixed brain slices were incubated overnight at 4°C with anti-NeuN antibody (1 : 250) (MABN140; RRID:AB_2571567) followed by incubation with Cy3-conjugated goat anti-rabbit IgG secondary antibody (1 : 400) (sc-2040; RRID:AB_631743) for 2 h at 20°C. TUNEL staining was performed using an in situ cell death detection kit (#11684795910) purchased from Roche-Sigma, St Louis, MO, USA, following the manufacturer's protocol. Finally, the sections were incubated with DAPI (1 : 2000) . The number of cells double-labeled with TUNEL and NeuN signal in each field was calculated at 940 magnification imaged via a confocal scanning microscope (IX81; Olympus) by an investigator blinded to the experimental design. The ratio of TUNEL and NeuN double-positive cells/NeuN-positive cells were totaled for five brain slices from every mouse. Similar cortical sections from six mice in every experimental group were assessed, and the average percentage of TUNEL+ and NeuN+/Total NeuN+ was statistically analyzed.
Dissociation and fluorescence-activated cell sorting (FACS) FVB/N-Tg(GFAPGFP)14Mes/J mice were used for isolating astrocytes. A single-cell suspension from the cortex and hippocampus was prepared as previously described (Xia et al. 2017) . In brief, tissue from three mice was pooled for one sample. Wavelengths of 488 nm and 530/30 nm were used for GFP excitation and emission, respectively. GFP + cells were sorted and collected. The purity of astrocytes sorted by this method has been confirmed in our previous works (Fu et al. 2012) by measuring the mRNA expression of cell markers of astrocytes, neurons, and oligodendrocytes.
Western blotting
Western blotting was performed as previously described (Li et al. 2011 (Li et al. , 2016 . After being blocked with powdered skim milk, sections were cultured for 2 h with the primary antibodies at 20°C. After the sections were washed, specific binding were detected with goat anti-rabbit (sc-2007; RRID:AB_631740) or goat anti-mouse (sc-2005; RRID:AB_631736) horseradish peroxidase-conjugated secondary antibodies. Staining was visualized with enhanced chemiluminescence detection reagents, and images were acquired with an electrophoresis gel imaging analysis system. Band density was measured in Windows AlphaEase FC 32-bit software.
Enzyme-linked immunosorbent assay
As we have described previously (Xia and Zhu 2015; Li et al. 2016) , IL-1b, IL-18, and tumor necrosis factor-alpha (TNF-a) in the culture supernatant or in the tissues were measured with mouse IL1b (MLB00C), IL-18 (#7625), and TNF-a (ΜΤΑ00Β) immunoassay kits (R & D Systems, Minneapolis, MN, USA). In brief, the measurement was conducted according to the manufacturer's protocol. Samples were collected in pyrogen/endotoxin-free tubes. The lower limits of detection for IL-1b, IL-18, and TNF-a were < 5, < 25, and < 8 pg/mL, respectively.
Statistics
Western blotting, ELISA and the quantification of immunofluorescence and TUNEL staining were performed by an investigator blinded to the experimental conditions. Differences between multiple groups with one or two variables were evaluated by one-way or two-way analysis of variance (ANOVA) followed by Fisher's least significant difference or a Tukey-Kramer post hoc multiple comparison test for unequal replications using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA). Sample size was not pre-determined by formal power calculation, and no samples or data were excluded from the analysis. All statistical data in the text are expressed as the mean AE SEM; the level of significance was set at p < 0.05.
Results

Sleep deprivation induces expression of NLRP3 inflammasome-related proteins
To characterize the effect of SD on astrocytes (Fig. 1a) , we used FACS to purify astrocytes from FVB/N-Tg(GFAPGFP) 14Mes/J transgenic mice, which express green fluorescent protein (GFP) in a subpopulation of astroglia. Fluorescence images of the cortex of GFAP-GFP mice are shown in Fig. 1 (b). Chronic treatment with SD for 1-5 weeks increased the expression of astroglial caspase 1 in a timedependent manner (Fig. 1c) . After 1 or 2 weeks of SD, expression of caspase 1 protein increased by 75 AE 5.2% or 117 AE 4.9% (n = 6), respectively, of the level in the sham group. After 3-5 weeks of SD, the level of caspase 1 was elevated by approximately 200%, with no significant difference among 3, 4, and 5 weeks groups (Fig. 1d) . According to this result, we chose 3 weeks of SD treatment for subsequent tests. Three weeks of SD significantly increased the expression of proteins of the NLRP3 inflammasome and pro-caspase 1 (Fig. 1e) . Expression of NLRP3 protein increased by 146 AE 7.3% (n = 6), while no significant changes in the levels of ASC or pro-caspase 1 were detected (Fig. 1f) .
Fluoxetine reduces neuroinflammatory markers induced by sleep deprivation Sleep deprivation of 3 weeks elevated the levels of IL-1b and IL-18 in FACS sorted astrocytes to 1634 AE 75.2% (n = 6) and 2503 AE 128.5% (n = 6) of control group, Fig. 1 The expression and function of nucleotide-binding domain and leucine-rich repeat protein-3 (NLRP3) inflammasomes in a sleep deprivation (SD) model treated with or without fluoxetine. Astrocytes were dissociated and separated from FVB/N-Tg(GFAPGFP)14Mes/J mice, which selectively express green fluorescent protein (GFP), in order to conduct the measurements (a). Representative immunofluorescence image of brain sections from GFAP-GFP mice, showing GFP (green) and DAPI (blue) in the cerebral cortex (b). Scale bar, 20 lm. After GFAP-GFP mice were treated with SD for 1-5 weeks, protein expression of caspase 1 was present, as shown in this representative blot; bands of 10 and 42 kDa represent caspase 1 and b-actin, respectively (c). The average protein level was quantified as the ratio of caspase 1 to b-actin in the astrocytes purified from GFAP-GFP mice (d). *p < 0.05, statistically significantly different compared with the sham, 1 or 2-week group; # p < 0.05, statistically significantly different compared with any other group. Data represent the mean AE SEM. The number of animals in every group was 6, n = 6. GFAP-GFP mice treated with SD for 3 weeks were used for the following experiments (e). Representative immunoblots for NLRP3, apoptosis-associated specklike protein containing a CARD (ASC) and pro-caspase 1 in astrocytes sorted from GFAP-GFP mice treated with SD for 3 weeks are shown in (e); bands of 120, 25, 45, and 42 kDa represent NLRP3, ASC, procaspase 1, and b-actin, respectively. Average protein levels were normalized to the level of b-actin (f). *p < 0.05, statistically significantly different compared with the sham group. Data represent the mean AE SEM. The number of animals in every group was 6, n = 6. respectively (Fig. 2a) . Intraperitoneal daily injections of 10 mg/kg fluoxetine during third week of SD treatment (Li et al. 2013) , partly alleviated the effect of SD on the upregulation of IL-1b and IL-18. The level of IL-1b was approximately nine times that of the control group, and the level of IL-18 was 1706 AE 93.1% (n = 6) of control group ( Fig. 2a and b) . The inhibiting effect of fluoxetine on IL-1b and IL-18 levels was dose dependent (Figure S2a and b) . Treatment with fluoxetine at 1, 10, or 100 mg/kg significantly suppressed the SD-induced elevation of IL-1b and IL-18 in purified astrocytes.
We also quantified the neuronal impairment triggered by SD using a TUNEL assay. As shown in Fig. 2(c) and (d) , the apoptosis of neurons labeled by the marker NeuN was significantly increased in the frontal cortex of the SD group (red arrows); the average percentage of TUNEL+ and NeuN+/Total NeuN+ was 7.9 AE 0.91% (n = 6), whereas in the control group it was only 1.4 AE 0.47% (n = 6). Treatment with fluoxetine at 10 mg/kg significantly decreased the neuronal apoptosis induced by SD (Fig. 2f) ; the percentage of TUNEL+ and NeuN+/Total NeuN+ decreased to 5.5 AE 0.52% (n = 6) (Fig. 2g) . However, treatment with fluoxetine alone had no effect on the level of apoptosis (Fig. 2e) .
Effects of SD and fluoxetine treatment on ERK 1/2 , AKT, GSK3b and STAT3 Sleep deprivation does not affect the phosphorylation of ERK 1/2 (Fig. 3a-c) , while significantly decreasing phosphorylation of AKT (by 50 AE 2.3%, n = 6 Fig. 3d) , and increasing phosphorylation of GSK-3b at Tyr216 (excitatory phosphorylation site) (by 115 AE 9.2% (n = 6), Fig. 3e ). At the same time, phosphorylation of STAT3 at Tyr705 (excitatory phosphorylation site) was suppressed by 52 AE 7.3%, n = 6 (Fig. 3f) . However, animals treated with fluoxetine alone had almost inverted effects compared with the SD-treated group; treatment with fluoxetine increased the phosphorylation of AKT by 112 AE 5.1% (n = 6) of the level in the sham group, while treatment with both fluoxetine and SD enhanced AKT phosphorylation by 160 AE 11.7% (n = 6) of the level observed in the group that received SD only (Fig. 3d) . Conversely, fluoxetine reduced the
(k) Fig. 3 The phosphorylation of ERK 1/2 , AKT, GSK-3b, and signal transducer and activator of transcription 3 (STAT3) in sleep deprivation (SD) mice treated with or without fluoxetine. GFAP-green fluorescent protein (GFP) mice were treated with sham or SD stimulation for 3 weeks and were injected with normal saline or fluoxetine in the third week. Then, the astrocytes from GFAP-GFP mice were purified via fluorescenceactivated cell sorting and were used to measure protein expression via western blotting (a-f). Representative blots for p-ERK 1/2 and ERK 1/2 , p-AKT and AKT, p-GSK-3b and GSK-3b, and p-STAT3 and STAT3 are shown in (a), (d), (e), and (f), respectively. Average phosphorylation levels were quantified as the ratios of p-ERK 1 to ERK 1 (b), p-ERK 2 to ERK 2 (c), p-AKT to AKT (d), p-GSK-3b to GSK-3b (e), and p-STAT3 to STAT3 (f). *p < 0.05, statistically significantly different compared with the sham and SD groups (b and c); *p < 0.05, statistically significantly different compared with any other group (d, e, and f). Data represent the mean AE SEM. The number of animals in every group was 6, n = 6. In addition, immunofluorescent staining for p-STAT3 in the frontal cortex was present, as shown in (g-j). Immunohistochemical staining of phosphorylated STAT3 (green) is shown in cortical astrocytes (GFAP; red), with 4 0 ,6-diamidine-2-phenylindole (blue) as a nuclear marker (g-j).
Scale bar, 50 lm. p-STAT3 immunolabeling intensity normalized to the intensity of the control group was analyzed in (k). *p < 0.05, statistically significantly different compared with any other group. Data represent the mean AE SEM. The number of animals in every group was 6, n = 6.
phosphorylation of GSK-3b by 40 AE 2.4% (n = 6) of the sham group value and by 22 AE 5.1% of the SD group value (Fig. 3e) . Similarly, fluoxetine elevated the phosphorylation of STAT3 by 133 AE 10.9% (n = 6) of the sham group level and by 214 AE 17.3% (n = 6) of the SD group (Fig. 3f) . Meanwhile, the stimulatory effect of fluoxetine on the phosphorylation of STAT3-which counteracted the effect of SD was also dose dependent ( Figure S2c and d) . Moreover, fluoxetine induced the phosphorylation of ERK 1/2 by 39 AE 7.5% (n = 6) and 46 AE 9.0% (n = 6) of the sham group value, and fluoxetine with or without SD treatment also had a similar effect on the phosphorylation of ERK 1/2 (Fig. 3a-c) .
We also used immunofluorescence to examine the phosphorylation level of STAT3, as shown in Fig. 3(g-k) . In the frontal cortex, the astrocytic fluorescence intensity of p-STAT3 was identified by the specific marker GFAP. The phosphorylation of STAT3 increased in astrocytes, marked by red arrows, and in non-astrocytes, indicated by white arrows. The background intensity of each image was measured in cell-free parenchyma in the same field of view and subtracted from the total immunofluorescence intensity. The intensity of p-STAT3 immunofluorescence in astrocytes from the different groups was normalized to the intensity of the sham group. As shown in Fig. 3 , in the SD group (Fig. 3h) , the intensity of p-STAT3 was significantly decreased by 29 AE 7.5% (n = 6) of the sham group value (Fig. 3g) . However, the intensity was increased by 157 AE 12.2% (n = 6) in the fluoxetine-treated group (Fig. 3i) , and the intensity was increased by 101 AE 10.8% (n = 6) in the SD animals treated with fluoxetine (Fig. 3j) .
Effects of fluoxetine on primary cultured astrocytes
In cultured cerebral astrocytes, fluoxetine increased the phosphorylation of ERK 1/2 and AKT at 10 lM ( Fig. 4a and  d) ; furthermore, 10 lM U0126 (an inhibitor of MAPK) and 10 lM LY294002 (an inhibitor of PI3K) both abolished the effect of fluoxetine on p-ERK 1/2 and p-AKT (Fig. 4a-e) . However, the regulatory effect of fluoxetine on the activation of p-GSK-3b was the opposite of its effect on p-AKT (Fig. 4e) . Fluoxetine suppressed the phosphorylation of GSK-3b by 66 AE 2.2% (n = 6) of the control group value (Fig. 4f) , and LY294002 (LY) completely abolished the effect of fluoxetine. Moreover, fluoxetine elevated the phosphorylation of STAT3 by 102 AE 9.1% (n = 6) of the control group value (Fig. 4h) , while U0126 and LY partly inhibited the activation of STAT3 induced by fluoxetine ( Fig. 4g and h ).
The regulation of P2X7R in the expression of NLRP3 inflammasome To verify the contribution of P2X 7 Rs to the activation of the NLRP3 inflammasome in SD, we used P2X 7 receptor knockout (P2X 7 R-KO) mice. Total protein from the cortex and hippocampus was collected for the western blot (Fig. 5a ). The effect of SD significantly increased the expression of NLRP3 and caspase 1 by 153 AE 6.9% (n = 6) and 115 AE 7.1% (n = 6) of the sham group level, respectively (Fig. 5b) . However, in P2X7R-KO mice, SD only elevated the levels of NLRP3 and caspase 1 by 65 AE 9.2% (n = 6) and 67 AE 5.7% (n = 6) of the sham group level, respectively (Fig. 5b) , and SD still had no effect on the protein levels of ASC and pro-caspase 1.
We further examined the effect of STAT3 activation on the NLRP3 inflammasome using 100 lM BzATP, an agonist of P2X 7 R (Yue et al. 2017) , to stimulate expression of the NLRP3 inflammasome (Fig. 5c) . BzATP increased the protein expression of NLRP3 and caspase 1 by 127 AE 7.3% (n = 6) and 202 AE 7.1% (n = 6) of the control group level (Fig. 5d ). However, a selective STAT3 activator colivelin administered at 10 nM (Chiu et al. 2016) ) significantly suppressed the effect of BzATP; the expression of NLRP3 was decreased by 38 AE 4.7% (n = 6) of the level found in the BzATP-treated group, and the level of caspase 1 was reduced by 41 AE 5.3%, n = 6 (Fig. 5d) .
Effect of fluoxetine on the expression and function of the NLRP3 inflammasome in an SD model
To further corroborate the findings from cultured astroglia, we investigated FACS sorted astrocytes obtained from mice subjected to SD. As shown in Fig. 6(a) , fluoxetine significantly decreased the expression of NLRP3 and caspase 1, respectively, by 41 AE 4.8% and 46 AE 5.4% (n = 6) of the levels in the SD-treated group (Fig. 6b and d) . However, U0126 and LY partly suppressed effects of fluoxetine. After pre-treatment with U0126 or LY, respectively, the expression of NLRP3 was increased by 34 AE 5.3% and 67 AE 7.3% (n = 6) of the level in the SD plus fluoxetine group (Fig. 6b) , and the level of caspase 1 was elevated by 23 AE 6.9% and 19 AE 4.1% (n = 6) of the level in the SD plus fluoxetine group (Fig. 6d) . However, SD-treated animals with or without fluoxetine had no significant effect on the expression of ASC or pro-caspase 1 (Fig. 6c and e) .
Fluoxetine suppressed the level of IL-1b and IL-18, respectively, by 44 AE 4.7% and 36 AE 5.5% (n = 6) of the values in the SD-treated group (Fig. 7a and b) , and U0126 and LY both partly decreased the effect of fluoxetine. However, the level of TNF-a in the sorted astrocytes was affected neither in the SD group nor in animals treated with fluoxetine (Fig. 7c) .
Discussion
In this study, we discovered that SD increased the expression of NLRP3 inflammasomes and the levels of IL-1b and IL-18 in astrocytes; furthermore, the SD increased neuronal apoptosis. Sleep deprivation stimulated formation of NLRP3 inflammasomes, with subsequent induction of the maturation Fig. 4 The regulatory effect of fluoxetine in primary cultured astrocytes. After pretreatment in serum-free medium with or without U0126 or LY294002 for 30 min, the astrocytes were cultured in the absence of any drug (Control) or in the presence of 1 lM fluoxetine for 3 days. Representative blots for p-ERK 1/2 and ERK 1/2 , p-AKT and AKT, p-GSK-3b and GSK-3b, and p-signal transducer and activator of transcription 3 (STAT3) and STAT3 are shown in (a), (d) and (g), respectively. Average phosphorylation levels were quantified as the ratios of p-ERK 1 to ERK 1 (b), p-ERK 2 to ERK 2 (c), p-AKT to AKT (e), p-GSK-3b to GSK-3b (f), and p-STAT3 to STAT3 (h). *p < 0.05, statistically significantly different compared with any other group (b, c, e, f, and h); # p < 0.05, statistically significantly different compared with the Control, Fluoxetine, U0126, or LY group (h). Data represent the mean AE SEM. The number of cell culture dishes in every group was 6, n = 6. of IL-1b and IL-18 (Fig. 8) , whereas treatment with the antidepressant fluoxetine inhibited the adverse effects of SD. We further demonstrated that P2X 7 R was involved in the SD-induced formation of NLRP3 inflammasomes, which may be attributed to the SD-promoted increase in extracellular ATP that activates P2X 7 R (Dworak et al. 2010; Karmakar et al. 2016) . The SD also decreased the activation of AKT and STAT3 but increased the activation of GSK-3b. Moreover, phosphorylated AKT inhibited the activation of GSK-3b, which suppresses the phosphorylation of STAT3 (Liu et al. 2015) . Therefore, the activation of STAT3 was decreased in the SD model; furthermore, stimulating the phosphorylation of STAT3 inhibited the expression of NLRP3 inflammasomes. However, treatment with fluoxetine stimulated the phosphorylation of STAT3 by activating the phosphorylation of ERK 1/2 and AKT; the phosphorylation of AKT induced by fluoxetine suppressed the activation of GSK-3b, thus increasing the activation of STAT3. The upregulation of STAT3 activation by fluoxetine, in turn, suppressed the expression of NLRP3 inflammasomes and maturation of IL-1b and IL-18 in astrocytes. Moreover, fluoxetine decreased the neuronal apoptosis induced by SD. Consequently, treatment with fluoxetine suppressed astroglial expression of neuroinflammatory markers induced by SD.
We further demonstrate that chronic SD stimulated the expression of the NLRP3 inflammasome and increased the levels of IL-1b and IL-18 in astrocytes purified from the cortex (Fig. 1) . Total IL-1b was previously found to be increased in the cortex after SD (Zielinski et al. 2017) . Similar results were obtained regarding the acute effects of SD on the elevation of caspase 1 and IL-1b in the cortex (Zielinski et al. 2017) . It is well known that sleep loss elevates the levels of sleep regulatory substances including IL-1b and TNF-a (Clinton et al. 2011) . At the same time, injection of IL-1b or TNF-a can induce symptoms associated with sleep deprivation (Clinton et al. 2011) . In this study, the administration of fluoxetine effectively decreased the levels Fig. 5 The activation of signal transducer and activator of transcription 3 was required for the stimulation of nucleotide-binding domain and leucine-rich repeat protein-3 (NLRP3) inflammasome expression by a P2X7 receptor agonist. B6 wild-type mice and P2X7 receptor knockout (P2X 7 R-KO) mice were treated with sleep deprivation (SD) for 3 weeks (a). After pre-treatment in serum-free medium with or without colivelin for 30 min, the astrocytes were cultured in the absence of any drug (Control) or in the presence of BzATP for 3 days (b). The protein expression of NLRP3 inflammasomes in the cortex (a) or in cultured astrocytes (b) was measured by western blotting. Data represent the mean AE SEM. The number of animals in every group was 6, n = 6.
Representative blots for the expression of NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), caspase 1, and pro-caspase 1 are shown in (a) and (c). of IL-1b and IL-18 in astrocytes by inhibiting the expression of activated NLRP3 inflammasomes. However, the level of TNF-a in astrocytes was not changed by SD. In previous studies, the relationship between SD and fluoxetine was mainly examined in relation to depressive disorders. Moreover, there is little evidence that the antidepressant fluoxetine can suppress the neuroinflammation induced by SD. In clinical experiments, patients treated with fluoxetine in addition to SD have shown greater improvement of depressive symptoms (Benedetti et al. 1997) . However, SD exerts its antidepressant activity mainly by stimulating the accumulation of serotonergic or noradrenergic neurotransmission, and depriving patients of sleep is clearly not suitable for long-term therapeutic treatment of depressive disorders (Hip olide et al. 2005; Conti et al. 2007 ). Long-term sleep deprivation is harmful to health and causes brain injury (Dworak et al. 2011; Armitage, 2007) . The timing of the short-term or long-term SD is yet to be identified, it has been suggested that the short-term is less than 24 h, while longterm SD exceeds 48 h (Junek et al. 2010) . P2X 7 R is shown to be expressed in neurons and astrocytes not only in vitro but also in vivo (Arbeloa et al. 2012; Illes et al. 2012; Hirayama et al. 2015; Ohishi et al. 2016) . Under mechanical trauma, stimulation of P2X 7 R triggers the activation of the NLRP3 inflammasome and the elevation of IL-1b in astrocytes (Albalawi et al. 2017) . Extracellular release of ATP is required for the sleep drive and occurs in response to a sleep deficit, with astrocytes being important for the wakefulness-dependent release of ATP (Schmitt et al. 2015) . In this work, we discovered that SD increased the astrocytic levels of IL-1b and IL-18 by stimulating the expression of the NLRP3 inflammasome, which could also be induced by BzATP activation of P2X 7 R in astrocytes. Extracellular ATP, associated with neuronal and glial signaling via P2X 7 R, has a role in the release of IL-1b and TNF-a (Clinton et al. 2011) , however, we did not find SD to have any effect on the level of TNF-a in astrocytes. Some nerve injuries such as neuropathic pain and SD cause the activation of microglia, which then release pro-inflammatory cytokines, for example, IL-6, IL1b, and TNF-a (Zhao et al. 2017) . The regulatory effect of SD on astrocytic expression of the NLRP3 inflammasome is the key point of this study; the effect of SD with or without fluoxetine on the microglia remains the matter for further research.
In this study, we found that SD decreased the activation of STAT3 and the administration of fluoxetine increased the activation of STAT3 in the cerebral astrocytes. Meanwhile, we also identified the activation of ERK 1/2 and AKT as being involved in the phosphorylation of STAT3 induced by fluoxetine in vivo and in vitro. However, as Fig. 3 shows, the increased phosphorylation of STAT3 in response to fluoxetine occurred not only in astrocytes (red arrows) but also in non-astrocytes (white arrows), which we speculate to be mainly neurons based on their morphology. There have not been any reports that fluoxetine can increase the activation of p-STAT3 in neurons; this topic merits further investigation because some anti-inflammatory cytokines (such as IL-10) decrease neuronal apoptosis by activating the JAK-STAT3 pathway . Whether the stimulation of STAT3 phosphorylation by fluoxetine could have neuroprotective effects and whether the neuroprotective effect of fluoxetine is related to its therapeutic function for depressive disorder or sleep deprivation remain obscure. In a chronic depressive stress model, levels of 5-HT 2B receptors were selectively decreased, and fluoxetine restored their expression in astrocytes (Dong et al. 2015) . According to previous reports, astrocytes are the key location where the antidepressant fluoxetine exerts its therapeutic effects (Peng et al. 2014; Hertz et al. 2015) . Fluoxetine acutely increased the phosphorylation of ERK 1/2 in primary cultured astrocytes, it directly stimulated 5-HT 2B receptors and transactivated the phosphorylation of EGFR (Li et al. 2008; Peng et al. 2014) . In addition, stimulation of EGFR causes phosphorylation of receptor tyrosine kinases; the latter activate two major intracellular signaling pathways, namely, MAPK-ERK and PI3K-AKT. We found that the activation of ERK 1/2 and AKT in response to fluoxetine both increased the phosphorylation of STAT3, but the activated AKT inhibited the phosphorylation of GSK-3b, which, in turn, suppressed the activation of STAT3. Similar results, in which GSK-3b Fig. 8 The schematic diagram. Sleep deprivation (SD) activated the expression of NLRP3 inflammasomes in astrocytes, and the production of IL-1b and IL-18 correspondingly increased. SD inhibited the phosphorylation of AKT, which decreased the activation of GSK-3b; the latter, in turn, suppressed the phosphorylation of signal transducer and activator of transcription 3 (STAT3). In addition, the suppression of STAT3 phosphorylation was involved in the neuroinflammation stimulated by SD because the activation of STAT3 could inhibit the expression of NLRP3 inflammasomes. P2X7 receptor (P2X 7 R) was involved in the effect of SD on the expression of NLRP3 inflammasomes. Administration of the antidepressant fluoxetine reversed the neuroinflammation induced by SD. Fluoxetine stimulated the activation of ERK 1/2 and AKT; both of them increased the phosphorylation of STAT3, and the increased activation of AKT elevated the phosphorylation of STAT3 by inhibiting the activation of GSK-3b. Fluoxetine decreased the expression of NLRP3 inflammasomes and the production of IL-1b and IL-18 by stimulating the activation of STAT3.
inhibited the stimulation of STAT3, have been reported in a rat model of depression (Liu et al. 2015) .
Sleep loss and the associated fatigue severely affect quality of life (Lee et al. 2009) , and the rhythm of sleep is gradually being recognized as an indicator contributing to many diseases (Grandner et al. 2013) , to emotional health and mood (Goldstein and Walker 2014) . In this study, we discovered that the regulatory effect of fluoxetine on cerebral astrocytes played a key role in inhibiting the neuroinflammation induced by SD. Furthermore, the activation of STAT3 was an important target that regulated the expression of NLRP3 inflammasomes in an SD model treated with or without fluoxetine. Our present research suggests the possibility that fluoxetine could suppress the neuronal impairment induced by SD. However, whether the antidepressant fluoxetine can improve the quality of sleep and reduce the adverse effect of sleep deprivation still requires in-depth clinical research. All experiments were conducted in compliance with the ARRIVE guidelines.
Acknowledgments and conflict of interest disclosure
Supporting information
Additional Supporting Information may be found online in the supporting information tab for this article: Figure S1 . The experimental timeline. Figure S2 . The regulatory effect of fluoxetine on the function of SD was concentration dependent.
